- Trials with a EudraCT protocol (69)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
69 result(s) found for: Mass vaccination.
Displaying page 1 of 4.
EudraCT Number: 2020-002584-63 | Sponsor Protocol Number: VAC31518COV2001 | Start Date*: 2020-09-02 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults ... | |||||||||||||
Medical condition: Healthy Volunteers (Prevention of COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Restarted) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000413-17 | Sponsor Protocol Number: COVERS | Start Date*: 2021-02-24 |
Sponsor Name:Region Skåne - Kliniska Studier Sverige, Forum Söder | ||
Full Title: COVERS (COVID-Vaccination Efficiency Risk and Safety Study) - an open trial for follow-up of efficacy, risk and safety in persons who have been vaccinated against SARS-CoV-2 in Region Skåne with va... | ||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002691-39 | Sponsor Protocol Number: APHP200039 | Start Date*: 2022-04-27 | |||||||||||
Sponsor Name:Assistance Publique-Hôpitaux de Paris | |||||||||||||
Full Title: INTERVENTIONAL RESEARCH PROTOCOL INVOLVING HUMAN PARTICIPANTS CONCERNING A MEDICINAL PRODUCT FOR HUMAN USE | |||||||||||||
Medical condition: Obese adult patients with BMI ≥35 kg/m2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001393-31 | Sponsor Protocol Number: ABNCoV2-01 | Start Date*: 2021-08-12 | |||||||||||
Sponsor Name:Bavarian Nordic A/S | |||||||||||||
Full Title: An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects. | |||||||||||||
Medical condition: COVID-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000836-24 | Sponsor Protocol Number: IIV-406 | Start Date*: 2019-06-19 |
Sponsor Name:National Institute of Health and the Environment | ||
Full Title: Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults. | ||
Medical condition: Healthy volunteers above 25 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005504-36 | Sponsor Protocol Number: ABNCoV2-03 | Start Date*: 2022-09-19 | |||||||||||
Sponsor Name:Bavarian Nordic A/S | |||||||||||||
Full Title: Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized, Doubl... | |||||||||||||
Medical condition: COVID-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005576-35 | Sponsor Protocol Number: CP-PRO-CoVLP-021 | Start Date*: 2021-05-06 | |||||||||||
Sponsor Name:Medicago R&D Inc. | |||||||||||||
Full Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years o... | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013406-13 | Sponsor Protocol Number: GBM-DC-2009 | Start Date*: 2009-10-07 |
Sponsor Name:Masaryk University | ||
Full Title: First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study... | ||
Medical condition: Glioblastoma Multiforme | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002879-14 | Sponsor Protocol Number: BioVacSafe-Boostrix® | Start Date*: 2015-07-30 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: BioVacSafe-Boostrix®: een klinische studie om een reeks gegevens te regenereren die kenmerkend zijn voor klinische gebeurtenissen, fysiologische reacties en aangeboren en adaptieve immuunreacties v... | |||||||||||||
Medical condition: vaccin against diphtheria, tetanus and pertussis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000116-42 | Sponsor Protocol Number: BioVacSafe-QIV | Start Date*: 2017-03-02 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus... | |||||||||||||
Medical condition: Healthy Volunteers - a quadrivalent inactivated split virus influenza vaccine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003543-35 | Sponsor Protocol Number: BioVacSafe–FluadTM | Start Date*: 2014-09-23 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: A clinical study to generate a set of data characterising clinical events, physiological responses, and innate and adaptive immune responses following a single intramuscular immunisation with Fluad... | |||||||||||||
Medical condition: vaccin against influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001823-38 | Sponsor Protocol Number: IMS-267 | Start Date*: 2013-08-05 |
Sponsor Name:National Institute of Public Health and Environment (RIVM, the Netherlands) | ||
Full Title: Second meningococcal vaccination in Dutch children: Study to compare the tetravalent MenACWY-TT conjugate vaccine with the monovalent MenC-TT conjugate vaccine. | ||
Medical condition: The monovalent MenC-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal group C. The tetravelent MenACWY-TT vaccin administered in this study is used to... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002690-35 | Sponsor Protocol Number: OEV123 | Start Date*: 2017-05-08 | ||||||||||||||||
Sponsor Name:Scandinavian Biopharma AB | ||||||||||||||||||
Full Title: A randomized, placebo-controlled phase IIb (OEV 123) study to evaluate safety, immunogenicity, diagnostic methodology, and estimate vaccine efficacy of an oral enterotoxigenic Escherichia coli (ET... | ||||||||||||||||||
Medical condition: Healthy voluteers (prevention of diarrheal disease due to infection with enterotoxigenic E. coli [ETEC]) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004008-36 | Sponsor Protocol Number: VRV09 | Start Date*: 2020-09-07 | |||||||||||
Sponsor Name:Sanofi Pasteur SA | |||||||||||||
Full Title: Immunogenicity and Safety of a Purified Vero Rabies Vaccine– Serum Free (VRVg) Assessed with the Institut Pasteur du Cambodge (IPC: 2-2-2-0-0) and the Thai Red Cross (TRC: 2-2-2-0-2) Intradermal Re... | |||||||||||||
Medical condition: Rabies (Healthy Volunteers) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000035-23 | Sponsor Protocol Number: VLA2001-307 | Start Date*: 2022-04-11 | |||||||||||
Sponsor Name:Valneva Austria GmbH | |||||||||||||
Full Title: OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCI... | |||||||||||||
Medical condition: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001483-28 | Sponsor Protocol Number: VAC31518COV1001 | Start Date*: 2020-07-14 |
Sponsor Name:Janssen Vaccines & Prevention B.V. | ||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Ye... | ||
Medical condition: Healthy volunteers (Prevention of COVID-19) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005372-42 | Sponsor Protocol Number: HEPATOTRAS | Start Date*: 2012-04-10 | |||||||||||||||||||||
Sponsor Name:Fundación FISEVI | |||||||||||||||||||||||
Full Title: Open-label, phase III, randomized, clinical trial to evaluate the efficacy of two different HBV vaccination schemes in patients with hepatic cirrhosis candidates to liver transplantation (HEPATOTRAS) | |||||||||||||||||||||||
Medical condition: HBV inmunization in patients with cirrhosis candidates for liver transplantation. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001239-38 | Sponsor Protocol Number: CP-PRO-QVLP-012 | Start Date*: 2017-10-23 | |||||||||||
Sponsor Name:Medicago R&D Inc. | |||||||||||||
Full Title: A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64... | |||||||||||||
Medical condition: Seasonal influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001098-15 | Sponsor Protocol Number: CCRG14-001 | Start Date*: 2015-10-13 | ||||||||||||||||
Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
Full Title: Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma | ||||||||||||||||||
Medical condition: Newly diagnosed glioblastoma (WHO grade IV) in adults, treated with surgical resection and chemoradiation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005226-26 | Sponsor Protocol Number: HIPRA-HH-2 | Start Date*: 2021-11-15 | |||||||||||
Sponsor Name:HIPRA SCIENTIFIC | |||||||||||||
Full Title: A Phase IIb, double-blind, randomized, active controlled, multi-centre, non-inferiority trial followed by a Phase III, single arm, open label trial, to assess immunogenicity and safety of a booster... | |||||||||||||
Medical condition: SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
